Artelo Biosciences, Inc.

ARTL
$2.17 (-7.26%)
02:20 PM · May 15 · NASDAQ
#22 Solana Treasuries

Artelo Biosciences, Inc.

ARTL
#22 in Solana Treasuries
Solana Treasury Stock · NASDAQ · Solana Beach, US
$2.17 (-7.26%)
02:20 PM · May 15, 2026
SOL Holdings
1,525 SOL Treasury
Treasury Value
$135.87K
SOL per Share
0.0022
mNAV
34.85x
Market Cap
$4.74M
Enterprise Value
-$4.92M

Market Overview

Market Cap
Shares Outstanding
50-Day Moving Average
200-Day Moving Average
Average Volume (20 Days)
Beta (5Y)
  • Chart chart view
  • Table table view
  • Price
  • Market Cap MCap
  • Shares
Start Date
start date
to
End Date
start date
Date OPEN HIGH LOW CLOSE VWAP VOLUME %CHG $CHG
1D
5D
1M
3M
6M
YTD
1Y
5Y

Artelo Biosciences, Inc. Company Overview

Artelo Biosciences, Inc. (NASDAQ: ARTL) is a clinical-stage biopharmaceutical company developing treatments that modulate the endocannabinoid system, with a pipeline including ART27.13 (Phase 1b/2a anorexia-associated-with-cancer), ART12.11 (cocrystal cannabidiol for inflammatory bowel disease and PTSD), and ART26.12 (a fatty-acid-binding-protein-5 inhibitor with peer-reviewed efficacy across visceral, inflammatory, neuropathic, and joint pain models). Artelo recently regained Nasdaq listing compliance and entered an AI-driven research collaboration with ScienceMachine to identify novel FABP5 inhibitor mechanisms. The company holds Solana on its balance sheet.

Artelo Biosciences, Inc. website url Visit Website Artelo Biosciences, Inc. linkedin url Artelo Biosciences, Inc. twitter url
Stock Exchange NASDAQ
IPO Date 2019-06-21
Number of Employees 6
Headquarters Solana Beach, CA, US

Key Executives

Andrew Yates

Senior Vice President & Chief Scientific Officer
Andrew Yates linkedin Andrew Yates twitter

Steven D. Reich

Chief Medical Officer
Steven D. Reich linkedin Steven D. Reich twitter

Gregory D. Gorgas

President, Chief Executive Officer, Secretary & Director
Gregory D. Gorgas linkedin Gregory D. Gorgas twitter

Jason H. Baybutt

Senior Vice President of Finance
Jason H. Baybutt linkedin Jason H. Baybutt twitter

Mark E. Spring

Chief Financial Officer, Treasurer, Principal Financial Officer & Principal Accounting Officer
Mark E. Spring linkedin Mark E. Spring twitter

Featured Posts

View all articles

Press Releases

No press releases found.

Unlock Multi-Year Historical Data & Advanced Metrics
Professional subscribers get exclusive access to advanced data and tools designed to give them an edge in the market.
Multi-year historical data Data source URLs Custom index builder AI quarterly summaries Search & filter tools
View Plans — $29/mo

SEC Filings

Form Type Filed Accepted Source

ARTL Frequently Asked Questions

The next earnings report date for Artelo Biosciences, Inc. (ARTL) is scheduled for August 12, 2026. Stay up to date with ’s financial results and key announcements by visiting our Earnings Tracker or by subscribing to earnings alerts. Here we also provide ARTL earnings call summaries and transcripts.

As of September 30, 2025, Artelo Biosciences, Inc. holds approximately 1,524.69 SOL . For more comprehensive insights, you can track ARTL 's Solana holdings on our Solana Treasuries page.

The current stock price of Artelo Biosciences, Inc. (ARTL) is $2.17 as of 02:20 PM 15/05/26. For live stock updates and company rankings, view our Bitcoin mining stocks by market cap table.

The latest news for Artelo Biosciences, Inc. (ARTL) includes Artelo Biosciences Provides Business Update Outlining Upcoming Milestones and Reports 2026 First Quarter Financial Results published on May 14, 2026. For more details and ongoing updates, visit the ARTL news section.